Mounjaro vs Semaglutide – How Do They Compare for Weight Loss?

Obesity affects more than a billion people around the world, and it’s not just about weight — it’s about health. Carrying excess weight can increase the risk of serious conditions like type 2 diabetes, heart disease, and high blood pressure, making effective weight management more important than ever. While healthy eating and physical activity are still the foundation, many people need extra support to reach and maintain a healthier weight.

That’s where medications like Mounjaro (tirzepatide) and semaglutide come in. These injectable therapies have made headlines for helping patients lose a significant amount of weight — and for improving other aspects of metabolic health. While semaglutide is FDA-approved for weight loss under a different name, Mounjaro is currently approved for type 2 diabetes but is also being used off-label for obesity, with promising clinical results.

In this article, we take a closer look at Mounjaro vs semaglutide — how they work, what the research shows, how they compare in terms of results and side effects, and what patients and providers should know when considering these treatment options for long-term weight management.

Key Takeaways

• Mounjaro (tirzepatide) and semaglutide (Wegovy, Ozempic) are both once-weekly injectable medications that support significant weight loss and improved metabolic health.
• Mounjaro’s dual GIP/GLP-1 mechanism may offer additional metabolic benefits, though the unique role of GIP activation is still being studied.
• Semaglutide works through GLP-1 receptor activation and has a well-established track record with broad real-world availability.
• In clinical trials, tirzepatide (SURMOUNT-1) showed up to 22% average weight loss, while semaglutide (STEP-1) resulted in around 15%—though these trials were not head-to-head comparisons.
• Both drugs share similar gastrointestinal side effects, and both carry boxed warnings related to thyroid cancer risk and MEN2.
• Semaglutide’s prescribing information includes specific warnings for gallbladder disease and diabetic retinopathy; tirzepatide’s long-term safety profile is still evolving.
• Cost and insurance coverage often influence treatment choice, with semaglutide having broader current access. Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for weight loss.
• The decision between Mounjaro and semaglutide depends on individual health goals, treatment response, and coverage logistics, guided by ongoing support from healthcare providers.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to order Mounjaro online for your practice, contact Doctor Medica today. 

Mechanistic Differences: Mounjaro’s Dual GIP/GLP-1 vs Semaglutide’s GLP-1

A key difference between tirzepatide (Mounjaro) and semaglutide lies in how each medication works within the body. Both belong to the class of incretin-based therapies, but they target the gut hormone pathways in different ways.

Semaglutide, available as Ozempic and Wegovy, is a GLP-1 receptor agonist. It helps lower blood sugar by increasing insulin secretion, reducing glucagon levels, and slowing how quickly food moves through the stomach. These effects also help reduce appetite and support weight loss.

Tirzepatide, branded as Mounjaro for type 2 diabetes, is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 and GIP pathways, with the potential to influence insulin sensitivity, energy balance, and fat metabolism. While clinical trials show that this dual action is associated with greater weight loss, researchers are still evaluating the independent role of GIP agonism in those outcomes.

For patients considering Mounjaro versus Wegovy, understanding these underlying mechanisms offers valuable insight. Semaglutide has a well-established track record, while tirzepatide represents a newer, more complex approach that may broaden treatment options in the future.

Comparative Efficacy: Weight Loss Outcomes (SURMOUNT vs STEP)

There are no published head-to-head clinical trials comparing semaglutide and tirzepatide directly. However, separate studies offer a useful look at how each medication performs.

In the SURMOUNT-1 trial, adults with obesity or overweight taking tirzepatide lost an average of 15 to 22% of their body weight over 72 weeks, depending on the dose. A significant number of participants achieved reductions of more than 20%, nearing the outcomes seen with bariatric procedures.

In contrast, the STEP-1 trial with semaglutide 2.4 mg (Wegovy) showed an average weight loss of about 15% over 68 weeks. This was a groundbreaking result in its own right, setting a new standard for anti-obesity medications at the time.

Although not directly compared, these results suggest that tirzepatide may offer additional weight loss potential. Still, semaglutide remains a highly effective and accessible therapy, with a strong safety record and broader real-world use.

Safety and Tolerability Profiles of Mounjaro and Semaglutide

When it comes to long-term success, safety and tolerability are just as important as effectiveness. Both semaglutide and tirzepatide share common side effects, especially during dose escalation.

Shared Side Effects

• Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, are the most frequently reported.
  
• These effects often ease over time, particularly with gradual dose increases and supportive measures like eating smaller meals and staying hydrated.
  
• GI side effects can impact adherence, which is why patient education and close monitoring are critical at the start of treatment.

Semaglutide-specific Considerations

• The prescribing label for semaglutide includes warnings for gallbladder disease, including gallstones.
  
• Rapid improvements in blood sugar control may worsen diabetic retinopathy in some patients, requiring extra attention for those with preexisting eye conditions.

Mounjaro-specific Considerations

• Patients sometimes report slightly higher rates of GI discomfort, particularly at higher doses.
  
• As a newer medication, tirzepatide’s long-term safety profile is still developing, though early data have been promising.

Boxed Warnings

• Both drugs carry boxed warnings related to medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
  
• Neither medication should be used in individuals with a personal or family history of these conditions.

Patient response and tolerance vary. A slow, steady increase in dosing often helps improve comfort and persistence with treatment. Importantly, neither medication has been linked to increased cardiovascular risk in trials to date.

Practical Considerations: Dosing Burden, Cost, Insurance, Patient Adherence

Beyond clinical performance, treatment decisions often come down to practical realities. Once-weekly dosing supports adherence for both drugs, but insurance coverage and out-of-pocket costs can be deciding factors.

• Tirzepatide is marketed as Mounjaro for type 2 diabetes and under the name Zepbound for chronic weight management.
  
• Semaglutide, as Ozempic and Wegovy, has been available longer and currently enjoys wider insurance support.
  
• Without coverage, both treatments can cost several hundred dollars per month, making affordability a key concern.
  
• Prior authorization and pharmacy access may delay treatment, so proactive provider support is important.

When comparing options, many patients weigh Mounjaro indications against their individual health goals, medical history, and what their insurance will approve. Provider guidance plays a crucial role in navigating these logistics and selecting the most suitable plan.

Conclusion

Tirzepatide and semaglutide represent major advancements in the medical treatment of obesity and related conditions. These medications offer substantial weight loss, improvements in blood sugar, and benefits for overall metabolic health—results once only achievable through surgery.

Early trial data show tirzepatide may lead to even greater weight reductions, with SURMOUNT-1 reporting body weight decreases of up to 22%. These findings have generated excitement about its role in both diabetes and obesity care. However, semaglutide’s consistent results and widespread availability make it a reliable choice that remains central to many care plans.

The best choice depends on a variety of factors, from a patient’s medical profile to their insurance coverage. With proper support and monitoring, both options empower patients to take meaningful steps toward long-term health.

FAQs

1. Which medication leads to more weight loss: Mounjaro or Semaglutide?

Tirzepatide has shown greater average weight loss in clinical trials, with reductions of up to 22% in the SURMOUNT studies. However, no direct head-to-head trial has been published yet.

2. Are both drugs FDA-approved for weight loss?

Semaglutide (Wegovy) is FDA-approved for chronic weight management. Tirzepatide is approved as Mounjaro for type 2 diabetes and under the name Zepbound for weight management.

3. Do Mounjaro and Semaglutide have similar side effects?

Both medications can cause gastrointestinal side effects like nausea and diarrhea. Tirzepatide may cause slightly more GI symptoms, while semaglutide has warnings about gallbladder issues and potential worsening of diabetic retinopathy.

4. How do cost and insurance affect the choice between the two?

Semaglutide generally has wider insurance coverage. Tirzepatide access is growing, but coverage may vary. Without insurance, both can be expensive, so affordability and approval are often part of the decision process.

References

World Health Organization: WHO. Obesity and overweight. Updated May 7, 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, A New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. doi:10.3390/molecules27134315

Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obesity and Metabolism. 2022;25(1):18-35. doi:10.1111/dom.14863